~~<i id='3E65BC4EF7'><strike id='3E65BC4EF7'><tt id='3E65BC4EF7'><pre id='3E65BC4EF7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：knowledge 2025-10-01 23:39:19 - browse：468

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： STAT Summit: Ending the crisis of Black deaths in the U.S.

focus

explore

Wikipedia

leisure time

focus

explore

DavidGoldman/APThenation’shealthfacesadualthreat—oneanticipated,theother,self-inflicted.Covid-19hasn

WSS

Why a market frenzy over new weight loss drugs defies logic

New details revealed about Purdue's marketing of OxyContin

Readout LOUD podcast: Live from the 2023 STAT Summit

Trump cancels press conference intended to dispute Georgia election interference charges

STAT Summit: Ending the crisis of Black deaths in the U.S.

Roche drug slashes death risk in early

hotspot

focus

focus

Trump demands the U.S. pay no more for drugs than other countries … again

ADCs take center stage as promising cancer treatments

Tori Bowie and the unacceptable rates of Black maternal death

New definition of a human embryo proposed amid rapid advances

Medical leaders decry Supreme Court decision on affirmative action

Trump's false claims about Georgia's 2020 election long debunked

ChatGPT in medicine: STAT answers readers' burning questions

Trump's false claims about Georgia's 2020 election long debunked

Duchenne breakthrough therapy leaves behind pioneering families

Cassava Sciences’ Alzheimer’s clinical trials should be halted

explore

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Hilary expected to bring catastrophic, life

Trump's false claims about Georgia's 2020 election long debunked

STAT Summit: The economic case for universal basic health care

Evacuations in place as 3 wildfires burn in eastern Washington state

Wikipedia

leisure time

focus

explore